GlassScriptPhysician profile
Suma B Ghanta
NPI 1609818756
$11,694.43
in general payments reported to CMS, 2019-2025
33 companies · $1,722 in 2025
The $1,722 reported for 2025 was more than what 96% of General Practice providers received nationally (typical 2025 total: $105).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,251 · 2020: $893 · 2021: $1,698 · 2022: $1,817 · 2023: $2,347 · 2024: $1,966 · 2025: $1,722.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,035.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,034.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $3,104.92 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $1,820.66 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $1,106.47 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $884.64 | 2019-2025 | Jardiance, Synjardy, Stiolto Respimat |
| Glaxosmithkline, LLC. | $711.41 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Pfizer INC. | $641.34 | 2019-2025 | |
| Lilly USA, LLC | $482.17 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Otsuka America Pharmaceutical, INC. | $399.81 | 2021-2025 | Rexulti |
| Merck Sharp & Dohme LLC | $332.13 | 2019-2025 | Gardasil 9, Gardasil, Capvaxive |
| Amgen INC. | $277.89 | 2019-2025 | Evenity, Repatha, Otezla |
| Axsome Therapeutics, INC. | $226.75 | 2024-2025 | Auvelity |
| Janssen Pharmaceuticals, INC | $200.78 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $192.54 | 2022-2025 | |
| Exact Sciences Corporation | $168.85 | 2023-2025 | Cologuard Collection Kit |
| Currax Pharmaceuticals LLC | $158.25 | 2021-2025 | Contrave |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $154.49 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $146.65 | 2022-2023 | Xifaxan |
| Teva Pharmaceuticals USA, INC. | $105.67 | 2019-2020 | |
| Heartflow, INC. | $98.53 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $90.16 | 2021-2022 | |
| Biohaven Pharmaceuticals, INC. | $71.58 | 2021 | |
| Bausch Health US, LLC | $50.75 | 2022-2025 | Wellbutrin |
| Astellas Pharma US INC | $42.75 | 2024 | Veozah |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $38.61 | 2025 | Caplyta |
| Seqirus USA INC | $35.10 | 2022-2025 | Flucelvax, Fluad |
| Althera Pharmaceuticals LLC | $28.90 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $26.33 | 2019-2021 | |
| Lundbeck LLC | $18.42 | 2025 | Rexulti |
| Xeris Pharmaceuticals, INC. | $16.95 | 2025 | Gvoke Hypopen |
| Mylan Specialty L.P. | $16.58 | 2022 | |
| Esperion Therapeutics, INC. | $15.00 | 2021 | |
| Cranial Technologies, INC | $15.00 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.35 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suma Ghanta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.